Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Effects of a Theanine Formulation on Stress, Burnout, Mood, and Sleep in Individuals Who Report Occasional Moderate or High Levels of Stress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ambulatory, male or female, 21-65 years of age~2. A BMI of 18.5-34.9~3. Admits to having occasional periods of moderate or severe stress~4. Indicating a DASS score \> 19 (identification as having moderate, severe, or extremely severe stress)~5. Indicating a PSS-14 score \> 19 (identification as having moderate or high perceived stress)~6. Have personal access to and able to operate a smartphone, tablet, or computer with enough memory to accommodate additional application(s) and have a reliable internet service~7. Able to print out and return documents by email (preferred)or mail~8. If have a history of testing positive for coronavirus SARS-CoV2 (COVID-19, being asymptomatic for a minimum of 14 days and have a negative COVID-19 antigen test~9. Able to take saliva specimens with a swab and store them immediately in a freezer before breakfast, lunch, dinner, and bedtime on four different days during the study~10. Generally healthy and having no difficulty swallowing a tablet~11. Have sufficient freezer space to hold a minimum of 2 saliva test kits (approximately the size of 2 ice cream cartons)~12. Has regular daytime work hours or shifts, if employed (regular shift excludes night shift workers and those with rotating shifts)~13. Has been generally weight stable for the past six months (+/- 6 lbs.)~14. Willing and able to give written informed consent~15. Clearly understands the procedures and study requirements~16. Willing and able to comply with all study procedures, including following recommendations to maintain their usual diet and regular activity, as per protocol~17. Able to communicate, including reading, in English~18. Has not taken any nutritional supplements that may contain any of the active component of the study product including L-theanine for a minimum of 14 days before Screening/baseline and for the duration of the study period~Exclusion Criteria:~1. Not having the basic skills needed to operate a smartphone, tablet, or computer~2. Unwilling to limit daily caffeine intake to less than 400 mg caffeine per day (\~ 95 mg caffeine in a cup of regular coffee) and refrain from consuming any caffeinated beverages/foods after 2 PM daily for the duration of the study~3. Having smoked any cigarette, electronic cigarette, cigar, pipe, or used a recreational drug as well as any product containing cannabidiol (CBD) or tetrahydrocannabinol (THC) in the past 30 days prior to Screening/baseline~4. Having donated blood within 30 days before Screening/baseline~5. Having been diagnosed with dysphagia or difficulty swallowing~6. Having participated in another study within 30 days prior to Screening/baseline~7. Being pregnant or planning on becoming pregnant during study participation; or breast feeding~8. History of allergy or sensitivity to any component of the study products including L-theanine, microcrystalline cellulose, hydroxypropyl methylcellulose, stearic acid, silica, silicon dioxide, vegetable stearate, croscarmellose sodium or glycerin~9. Are not participating in a stress management program and will not for the duration of the study participation.~10. Unable to avoid any form of intense exercise or a significant change in your exercise routine during the day of saliva specimen collection~11. Currently taking supplements including melatonin, 5-hydroxytryptophan, Calamus, California poppy, St. John's wort, S-adenosylmethionine (SAM-E), catnip, hops, kava, valerian, Jamaican dogwood, skullcap, yerba mansa, Hawaiian baby woodrose, L-theanine, magnesium, or any other supplement for stress, burnout, mood, or sleep. These may preclude participation in the study dependent the judgment of the Study Investigator/Sub-Investigator~12. Having been diagnosed, received medical treatment, taking medication/supplements daily for the following medical condition(s):~    * Stress disorder (including post-traumatic stress disorder \[PTSD\])~   * Sleep disorder (including insomnia diagnosed by a physician)~   * Psychiatric disorder (bipolar disorder, manic disorder, schizophrenia, apathetic \[inherited\] disorder), that include antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs), tricyclic and atypical antidepressants; benzodiazepines; phenothiazines, central nervous system (CNS) depressants as well as the following medications: dextromethorphan, meperidine, monoamine oxidase inhibitors (MAOIs), pentazocine and tramadol. These may preclude participation in the study dependent on the judgment of the Study Investigator/Sub-Investigator.~   * Acute or chronic inflammatory or autoimmune disease (including rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, Sjögren's syndrome, polymyalgia rheumatica, inflammatory bowel disease, psoriatic arthritis, fibromyalgia, or chronic fatigue syndrome)~   * Active infection~   * Active periodontal disease~13. Presence of active or recurring clinically significant conditions as follows:~    * Diabetes mellitus (except on a stable dose of Metformin up to 1000 mg per day only for managing the diabetes mellitus for \> 3 months before Screening/baseline, unlikely to change medication or dose during the study, and under the care of a physician having seen the physician within 6 months before Screening/baseline)~   * Endocrine disease (other than diabetes mellitus)~   * Eating disorder~   * Cardiovascular disease including heart and blood vessel disease, arrhythmia, heart attack, stroke, or heart valve problem~   * Gastrointestinal disease including gallbladder problems, gallstones, or biliary tract obstruction~   * Thyroid disease (except on a stable dose of medication for ≥ 3 months before Screening/baseline and unlikely to change medication or dose during the study)~   * Hypertension (except on a stable dose of medication for ≥ 3 months before Screening/baseline and unlikely to change medication or dose during the study)~   * Neurologic condition/disease~   * Cancer (including skin cancer) which has been treated ≥ 5 years before Screening/baseline or at the discretion of the Study Investigator/Sub-Investigator~   * Liver, pancreatic, and kidney disease~   * Pulmonary disease~   * Blood coagulation disorder or other hematologic disease~   * Any other condition or medication that may preclude study participation in the judgement of the Study Investigator/Sub-Investigator~14. Currently taking or having taken within the 30 days before Screening/baseline any hormone replacement therapy (including dehydroepiandrosterone (DHEA), estrogen, progesterone, or testosterone), except those utilized as a method of birth control and which have been taken for \> 3 months with no anticipated change for the duration of the study period~15. Having had a surgical procedure or having an internal medical device which, in the judgment of the Study Investigator/Sub-Investigator, would preclude participation in the study~16. Currently consumes more than 4 standard alcoholic drinks per week for women and 7 drinks per week for men (a standard alcoholic drink is defined as one bottle/can of beer, one glass of wine, or one ounce of hard liquor)~17. Unable or unwilling to avoid consuming grapefruit juice or fresh grapefruit, Seville oranges, and tangelos for the duration of the study period~18. History of known or suspected substance abuse (e.g., alcohol, opiates, benzodiazepines, or amphetamines)~19. Having any other circumstance that may preclude study participation in the judgment of the Study Investigator/Sub-Investigator, including use of other nutritional supplements, which will be evaluated on a case-by-case basis

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): Dietary Supplement (Theanine Formulation)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility